1. Home
  2. KDP vs ARGX Comparison

KDP vs ARGX Comparison

Compare KDP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keurig Dr Pepper Inc.

KDP

Keurig Dr Pepper Inc.

HOLD

Current Price

$29.55

Market Cap

36.0B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$785.81

Market Cap

42.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KDP
ARGX
Founded
1981
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0B
42.9B
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
KDP
ARGX
Price
$29.55
$785.81
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$32.27
$1,008.56
AVG Volume (30 Days)
11.5M
275.3K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.18%
N/A
EPS Growth
45.71
N/A
EPS
0.20
N/A
Revenue
$16,603,000,000.00
N/A
Revenue This Year
$58.73
$44.39
Revenue Next Year
$14.29
$20.84
P/E Ratio
$144.63
$33.69
Revenue Growth
8.16
N/A
52 Week Low
$24.88
$510.06
52 Week High
$35.94
$934.62

Technical Indicators

Market Signals
Indicator
KDP
ARGX
Relative Strength Index (RSI) 68.44 50.92
Support Level $26.61 $770.67
Resistance Level $30.02 $855.57
Average True Range (ATR) 0.73 16.58
MACD 0.39 -5.31
Stochastic Oscillator 98.61 28.87

Price Performance

Historical Comparison
KDP
ARGX

About KDP Keurig Dr Pepper Inc.

Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. On Aug. 25, 2025, the firm announced a definitive agreement to acquire coffeemaker JDE Peet's for $18 billion in cash, with the deal now scheduled to close in April 2026. Following the merger, it plans to split into two US-listed entities to focus on refreshment beverages in North America and global coffee separately.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: